{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:48:46Z","timestamp":1776653326790,"version":"3.51.2"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Basic Science Research Program through the National Research Foundation of Korea","award":["RS-2020-NR049591"],"award-info":[{"award-number":["RS-2020-NR049591"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11418-x","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:23:05Z","timestamp":1768213385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging therapeutic strategies in muscular dystrophy: an updated review on pathogenesis and treatment advances"],"prefix":"10.1007","volume":"53","author":[{"given":"Shahid","family":"Parwez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khurshid","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"10","key":"11418_CR1","first-page":"e46860","volume":"15","author":"S Abdallah","year":"2023","unstructured":"Abdallah S et al (2023) The impact of artificial intelligence on optimizing diagnosis and treatment plans for rare genetic disorders. Cureus 15(10):e46860","journal-title":"Cureus"},{"issue":"10","key":"11418_CR2","doi-asserted-by":"publisher","first-page":"e1094","DOI":"10.1212\/WNL.0000000000009068","volume":"94","author":"J Verd\u00fa-D\u00edaz","year":"2020","unstructured":"Verd\u00fa-D\u00edaz J et al (2020) Accuracy of a machine learning muscle MRI-based tool for the diagnosis of muscular dystrophies. Neurology 94(10):e1094\u2013e1102","journal-title":"Neurology"},{"issue":"3","key":"11418_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.fmre.2024.04.021","volume":"5","author":"AU Rehman","year":"2025","unstructured":"Rehman AU et al (2025) Role of artificial intelligence in revolutionizing drug discovery. Fundam Res 5(3):1273\u20131287","journal-title":"Fundam Res"},{"issue":"6","key":"11418_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/bioengineering11060580","volume":"11","author":"A Mastropietro","year":"2024","unstructured":"Mastropietro A et al (2024) Classification of muscular dystrophies from MR images improves using the Swin transformer deep learning model. Bioengineering 11(6):580","journal-title":"Bioengineering"},{"issue":"1","key":"11418_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41591-022-02045-1","volume":"29","author":"V Ricotti","year":"2023","unstructured":"Ricotti V et al (2023) Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy. Nat Med 29(1):95\u2013103","journal-title":"Nat Med"},{"issue":"5","key":"11418_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4236\/abb.2024.155018","volume":"15","author":"R de Filippis","year":"2024","unstructured":"de Filippis R, Foysal AA (2024) Harnessing the power of artificial intelligence in neuromuscular disease rehabilitation: a comprehensive review and algorithmic approach. Adv Biosci Biotechnol 15(5):289\u2013309","journal-title":"Adv Biosci Biotechnol"},{"issue":"Suppl 15","key":"11418_CR7","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1212\/WNL.96.15_supplement.4478","volume":"96","author":"J Mendell","year":"2021","unstructured":"Mendell J, Shieh P, Sahenk Z, Lehman K, Lowes L, Miller N, Iammarino M, Alfano L, Woods J, Skura C, Mao H, Staudt L, Potter R, Griffin D, Lewis S, Hu L, Upadhyay S, Teji L, Rodino-Klapac LR (2021) A multicenter randomized, double-blind, placebo-controlled, gene-delivery clinical trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne muscular dystrophy. Neurology 96(Suppl 15):4478","journal-title":"Neurology"},{"issue":"1","key":"11418_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D et al (2021) Duchenne muscular dystrophy. Nat Rev Dis Primers 7(1):13","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"11418_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nmd.2006.10.003","volume":"17","author":"D Skuk","year":"2007","unstructured":"Skuk D et al (2007) First test of a high-density injection protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord 17(1):38\u201346","journal-title":"Neuromuscul Disord"},{"issue":"418","key":"11418_CR10","doi-asserted-by":"publisher","first-page":"eaan8081","DOI":"10.1126\/scitranslmed.aan8081","volume":"9","author":"L Amoasii","year":"2017","unstructured":"Amoasii L et al (2017) Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med 9(418):eaan8081","journal-title":"Sci Transl Med"},{"issue":"4","key":"11418_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.nmd.2019.02.002","volume":"29","author":"V Ricotti","year":"2019","unstructured":"Ricotti V et al (2019) Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: a prospective multicentre study. Neuromuscul Disord 29(4):261\u2013268","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"11418_CR12","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1172\/JCI37662","volume":"119","author":"SA Vetrone","year":"2009","unstructured":"Vetrone SA et al (2009) Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-\u03b2. J Clin Invest 119(6):1583\u20131594","journal-title":"J Clin Invest"},{"issue":"1","key":"11418_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2025","unstructured":"Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Guridi M, Murphy AP, Reid C, Wandel C, Asher DR, Darton E, Mason S, Potter RA, Singh T, Zhang W, Fontoura P, Elkins JS, Rodino-Klapac LR (2025) AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med 31(1):332\u2013341","journal-title":"Nat Med"},{"issue":"6271","key":"11418_CR14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long C et al (2016) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351(6271):400\u2013403","journal-title":"Science"},{"issue":"9\u201310","key":"11418_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/hum.2023.053","volume":"34","author":"F Chemello","year":"2023","unstructured":"Chemello F, Olson EN, Bassel-Duby R (2023) CRISPR-editing therapy for Duchenne muscular dystrophy. Hum Gene Ther 34(9\u201310):379\u2013387","journal-title":"Hum Gene Ther"},{"issue":"1","key":"11418_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/14712598.2022.2150543","volume":"23","author":"H Wilton-Clark","year":"2023","unstructured":"Wilton-Clark H, Yokota T (2023) Biological and genetic therapies for the treatment of Duchenne muscular dystrophy. Expert Opin Biol Ther 23(1):49\u201359","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"11418_CR17","doi-asserted-by":"publisher","first-page":"112968","DOI":"10.1016\/j.yexcr.2021.112968","volume":"410","author":"G Angelini","year":"2022","unstructured":"Angelini G, Mura G, Messina G (2022) Therapeutic approaches to preserve the musculature in Duchenne muscular dystrophy: the importance of the secondary therapies. Exp Cell Res 410(2):112968","journal-title":"Exp Cell Res"},{"issue":"8","key":"11418_CR18","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.ajpath.2024.04.006","volume":"194","author":"J-S You","year":"2024","unstructured":"You J-S et al (2024) Leucyl-tRNA synthetase contributes to muscle weakness through mammalian target of Rapamycin complex 1 activation and autophagy suppression in a mouse model of Duchenne muscular dystrophy. Am J Pathol 194(8):1571\u20131580","journal-title":"Am J Pathol"},{"issue":"1","key":"11418_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40120-023-00570-w","volume":"13","author":"F Muntoni","year":"2024","unstructured":"Muntoni F et al (2024) The clinical development of Taldefgrobep alfa: an anti-myostatin adnectin for the treatment of Duchenne muscular dystrophy. Neurol Ther 13(1):183\u2013219","journal-title":"Neurol Ther"},{"issue":"18","key":"11418_CR20","doi-asserted-by":"publisher","first-page":"eadj8042","DOI":"10.1126\/sciadv.adj8042","volume":"10","author":"A Granados","year":"2024","unstructured":"Granados A et al (2024) SETDB1 modulates the TGF\u03b2 response in Duchenne muscular dystrophy myotubes. Sci Adv 10(18):eadj8042","journal-title":"Sci Adv"},{"issue":"6","key":"11418_CR21","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/bph.15678","volume":"179","author":"Z Sun","year":"2022","unstructured":"Sun Z et al (2022) A new therapeutic effect of Fenofibrate in Duchenne muscular dystrophy: the promotion of myostatin degradation. Br J Pharmacol 179(6):1237\u20131250","journal-title":"Br J Pharmacol"},{"key":"11418_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fphar.2020.00142","volume":"11","author":"K Ahmad","year":"2020","unstructured":"Ahmad K et al (2020) Cross-talk between extracellular matrix and skeletal muscle: implications for myopathies. Front Pharmacol 11:142","journal-title":"Front Pharmacol"},{"issue":"11","key":"11418_CR23","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1007\/s11010-021-04216-z","volume":"476","author":"S Appunni","year":"2021","unstructured":"Appunni S et al (2021) Biglycan: an emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance. Mol Cell Biochem 476(11):3935\u20133950","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"11418_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3233\/JND-180341","volume":"6","author":"E Finanger","year":"2019","unstructured":"Finanger E et al (2019) Phase 1 study of Edasalonexent (CAT-1004), an oral NF-\u03baB inhibitor, in pediatric patients with Duchenne muscular dystrophy. J Neuromuscul Dis 6(1):43\u201354","journal-title":"J Neuromuscul Dis"},{"issue":"21","key":"11418_CR25","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.3390\/cells11213435","volume":"11","author":"C Battistelli","year":"2022","unstructured":"Battistelli C, Garbo S, Maione R (2022) MyoD-induced trans-differentiation: a paradigm for dissecting the molecular mechanisms of cell commitment, differentiation and reprogramming. Cells 11(21):3435","journal-title":"Cells"},{"issue":"4","key":"11418_CR26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/neurolint16040055","volume":"16","author":"L Krishna","year":"2024","unstructured":"Krishna L et al (2024) Molecular and biochemical therapeutic strategies for Duchenne muscular dystrophy. Neurol Int 16(4):731\u2013760","journal-title":"Neurol Int"},{"issue":"1","key":"11418_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40259-023-00632-3","volume":"38","author":"S Szwec","year":"2024","unstructured":"Szwec S et al (2024) Dystrophin- and utrophin-based therapeutic approaches for treatment of Duchenne muscular dystrophy: a comparative review. BioDrugs 38(1):95\u2013119","journal-title":"BioDrugs"},{"issue":"3","key":"11418_CR28","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3390\/ijms24032229","volume":"24","author":"MV Dubinin","year":"2023","unstructured":"Dubinin MV, Belosludtsev KN (2023) Ion channels of the sarcolemma and intracellular organelles in Duchenne muscular dystrophy: a role in the dysregulation of ion homeostasis and a possible target for therapy. Int J Mol Sci 24(3):2229","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11418_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais L et al (2022) Long-term safety and efficacy data of Golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial. Nucleic Acid Ther 32(1):29\u201339","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"11418_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JND-220811","volume":"9","author":"PR Clemens","year":"2022","unstructured":"Clemens PR et al (2022) Long-term functional efficacy and safety of Viltolarsen in patients with Duchenne muscular dystrophy. J Neuromuscul Dis 9(4):493\u2013501","journal-title":"J Neuromuscul Dis"},{"issue":"Suppl","key":"11418_CR31","first-page":"S102","volume":"32","author":"S Mercuri","year":"2022","unstructured":"Mercuri S et al (2022) Casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: interim results from the phase 3 ESSENCE trial. Neuromuscul Disord 32(Suppl):S102","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"11418_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","volume":"27","author":"K Dzierlega","year":"2020","unstructured":"Dzierlega K, Yokota T (2020) Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther 27(9):407\u2013416","journal-title":"Gene Ther"},{"issue":"5","key":"11418_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3390\/cells9051119","volume":"9","author":"A Klimczak","year":"2020","unstructured":"Klimczak A et al (2020) Co-transplantation of bone marrow-MSCs and myogenic stem\/progenitor cells from adult donors improves muscle function of patients with Duchenne muscular dystrophy. Cells 9(5):1119","journal-title":"Cells"},{"key":"11418_CR34","doi-asserted-by":"publisher","first-page":"100523","DOI":"10.1016\/j.cobme.2024.100523","volume":"30","author":"N Takenaka-Ninagawa","year":"2024","unstructured":"Takenaka-Ninagawa N et al (2024) Cell therapy for Duchenne muscular dystrophy using induced pluripotent stem cell-derived muscle stem cells and the potential of regenerative rehabilitation. Curr Opin Biomed Eng 30:100523","journal-title":"Curr Opin Biomed Eng"},{"key":"11418_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.hjc.2023.06.007","volume":"74","author":"CN Haddad","year":"2023","unstructured":"Haddad CN et al (2023) Pharmacological management of dilated cardiomyopathy in Duchenne muscular dystrophy: a systematic review. Hellenic J Cardiol 74:58\u201364","journal-title":"Hellenic J Cardiol"},{"issue":"6","key":"11418_CR36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/nan.12735","volume":"47","author":"P Soblechero-Mart\u00edn","year":"2021","unstructured":"Soblechero-Mart\u00edn P et al (2021) Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies. Neuropathol Appl Neurobiol 47(6):711\u2013723","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"11418_CR37","doi-asserted-by":"publisher","first-page":"e1580","DOI":"10.1002\/wsbm.1580","volume":"15","author":"YCJ Chey","year":"2023","unstructured":"Chey YCJ et al (2023) CRISPR applications for Duchenne muscular dystrophy: from animal models to potential therapies. WIREs Mech Dis 15(1):e1580","journal-title":"WIREs Mech Dis"},{"issue":"7","key":"11418_CR38","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/biomedicines12071407","volume":"12","author":"S Gandhi","year":"2024","unstructured":"Gandhi S, Sweeney G, Perry CGR (2024) Recent advances in pre-clinical development of adiponectin receptor agonist therapies for Duchenne muscular dystrophy. Biomedicines 12(7):1407","journal-title":"Biomedicines"},{"issue":"13","key":"11418_CR39","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.3390\/ijms21134596","volume":"21","author":"S Herbelet","year":"2020","unstructured":"Herbelet S et al (2020) Anti-inflammatory and general glucocorticoid physiology in skeletal muscles affected by Duchenne muscular dystrophy: exploration of steroid-sparing agents. Int J Mol Sci 21(13):4596","journal-title":"Int J Mol Sci"},{"key":"11418_CR40","doi-asserted-by":"publisher","first-page":"155350","DOI":"10.1016\/j.phymed.2024.155350","volume":"125","author":"K Ahmad","year":"2024","unstructured":"Ahmad K et al (2024) Licochalcone A and B enhance muscle proliferation and differentiation by regulating myostatin. Phytomedicine 125:155350","journal-title":"Phytomedicine"},{"issue":"1","key":"11418_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12964-021-00785-0","volume":"19","author":"MD Yazid","year":"2021","unstructured":"Yazid MD, Hung-Chih C (2021) Perturbation of PI3K\/Akt signaling affected autophagy modulation in dystrophin-deficient myoblasts. Cell Commun Signal 19(1):105","journal-title":"Cell Commun Signal"},{"issue":"21","key":"11418_CR42","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1007\/s00018-020-03537-4","volume":"77","author":"R Brusa","year":"2020","unstructured":"Brusa R et al (2020) Noncoding RNAs in Duchenne and Becker muscular dystrophies: role in pathogenesis and future prognostic and therapeutic perspectives. Cell Mol Life Sci 77(21):4299\u20134313","journal-title":"Cell Mol Life Sci"},{"key":"11418_CR43","first-page":"63","volume":"47","author":"W Lin","year":"2024","unstructured":"Lin W et al (2024) Wnt\/\u03b2-catenin signaling pathway as an important mediator in muscle and bone crosstalk: a systematic review. J Orthop Transl 47:63\u201373","journal-title":"J Orthop Transl"},{"issue":"2","key":"11418_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11897-022-00541-6","volume":"19","author":"T Lee-Gannon","year":"2022","unstructured":"Lee-Gannon T et al (2022) Biomarkers in Duchenne muscular dystrophy. Curr Heart Fail Rep 19(2):52\u201362","journal-title":"Curr Heart Fail Rep"},{"issue":"6","key":"11418_CR45","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/cells10061364","volume":"10","author":"N Mosca","year":"2021","unstructured":"Mosca N et al (2021) Redox homeostasis in muscular dystrophies. Cells 10(6):1364","journal-title":"Cells"},{"issue":"14","key":"11418_CR46","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/cells13141168","volume":"13","author":"S Gandhi","year":"2024","unstructured":"Gandhi S et al (2024) Cardiomyopathy in Duchenne muscular dystrophy and the potential for mitochondrial therapeutics to improve treatment response. Cells 13(14):1168","journal-title":"Cells"},{"issue":"2","key":"11418_CR47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jcsm.12527","volume":"11","author":"D Capitanio","year":"2020","unstructured":"Capitanio D et al (2020) Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. J Cachexia Sarcopenia Muscle 11(2):547\u2013563","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"11418_CR48","first-page":"431","volume":"14","author":"X Xu","year":"2021","unstructured":"Xu X et al (2021) Assessment of weighted gene co-expression network analysis to explore key pathways and novel biomarkers in muscular dystrophy. Pharmacogenomics Pers Med 14:431\u2013444","journal-title":"Pharmacogenomics Pers Med"},{"issue":"24","key":"11418_CR49","doi-asserted-by":"publisher","first-page":"13225","DOI":"10.3390\/ijms222413225","volume":"22","author":"X Xing","year":"2021","unstructured":"Xing X et al (2021) Disrupting the molecular pathway in myotonic dystrophy. Int J Mol Sci 22(24):13225","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11418_CR50","doi-asserted-by":"publisher","first-page":"e12876","DOI":"10.1111\/nan.12876","volume":"49","author":"J Tahraoui-Bories","year":"2023","unstructured":"Tahraoui-Bories J et al (2023) MBNL-dependent impaired development within the neuromuscular system in myotonic dystrophy type 1. Neuropathol Appl Neurobiol 49(1):e12876","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5","key":"11418_CR51","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.3390\/ijms24054306","volume":"24","author":"M Sandon\u00e0","year":"2023","unstructured":"Sandon\u00e0 M et al (2023) Histone deacetylases: molecular mechanisms and therapeutic implications for muscular dystrophies. Int J Mol Sci 24(5):4306","journal-title":"Int J Mol Sci"},{"issue":"5","key":"11418_CR52","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1093\/nar\/gkaa007","volume":"48","author":"E Stepniak-Konieczna","year":"2020","unstructured":"Stepniak-Konieczna E et al (2020) AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for myotonic dystrophy type 1. Nucleic Acids Res 48(5):2531\u20132543","journal-title":"Nucleic Acids Res"},{"issue":"22","key":"11418_CR53","doi-asserted-by":"publisher","first-page":"12594","DOI":"10.3390\/ijms222212594","volume":"22","author":"VV Visconti","year":"2021","unstructured":"Visconti VV et al (2021) Epigenetics of myotonic dystrophies: a minireview. Int J Mol Sci 22(22):12594","journal-title":"Int J Mol Sci"},{"key":"11418_CR54","doi-asserted-by":"publisher","first-page":"105055","DOI":"10.1016\/j.nbd.2020.105055","volume":"145","author":"ZT McEachin","year":"2020","unstructured":"McEachin ZT et al (2020) RNA-mediated toxicity in C9orf72 ALS and FTD. Neurobiol Dis 145:105055","journal-title":"Neurobiol Dis"},{"key":"11418_CR55","doi-asserted-by":"publisher","first-page":"1281953","DOI":"10.3389\/fneur.2023.1281953","volume":"14","author":"M Rimoldi","year":"2023","unstructured":"Rimoldi M et al (2023) Case report: a novel patient presenting TRIM32-related limb-girdle muscular dystrophy. Front Neurol 14:1281953","journal-title":"Front Neurol"},{"issue":"11","key":"11418_CR56","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/glycob\/cwad067","volume":"33","author":"M Koff","year":"2023","unstructured":"Koff M et al (2023) Protein O-mannosylation: one sugar, several pathways, many functions. Glycobiology 33(11):911\u2013926","journal-title":"Glycobiology"},{"issue":"14","key":"11418_CR57","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.3390\/jcm12144769","volume":"12","author":"C Bouchard","year":"2023","unstructured":"Bouchard C, Tremblay JP (2023) Limb-girdle muscular dystrophies classification and therapies. J Clin Med 12(14):4769","journal-title":"J Clin Med"},{"issue":"1","key":"11418_CR58","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12015-023-10653-8","volume":"20","author":"A Akat","year":"2024","unstructured":"Akat A, Kara\u00f6z E (2024) Cell therapy strategies on Duchenne muscular dystrophy: a systematic review of clinical applications. Stem Cell Rev Rep 20(1):138\u2013158","journal-title":"Stem Cell Rev Rep"},{"issue":"10","key":"11418_CR59","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/sctm.21-0027","volume":"10","author":"B \u015awi\u0105tkowska-Flis","year":"2021","unstructured":"\u015awi\u0105tkowska-Flis B et al (2021) The use of umbilical cord-derived mesenchymal stem cells in patients with muscular dystrophies: results from compassionate use in real-life settings. Stem Cells Transl Med 10(10):1372\u20131383","journal-title":"Stem Cells Transl Med"},{"key":"11418_CR60","doi-asserted-by":"publisher","first-page":"1248338","DOI":"10.3389\/fgene.2023.1248338","volume":"14","author":"N Chung Tran","year":"2023","unstructured":"Chung Tran N et al (2023) Novel mutations in the SGCA gene in unrelated Vietnamese patients with limb-girdle muscular dystrophies disease. Front Genet 14:1248338","journal-title":"Front Genet"},{"key":"11418_CR61","doi-asserted-by":"publisher","first-page":"174568","DOI":"10.1016\/j.ejphar.2021.174568","volume":"912","author":"S Singh","year":"2021","unstructured":"Singh S et al (2021) Gene-editing, immunological and iPSCs-based therapeutics for muscular dystrophy. Eur J Pharmacol 912:174568","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"11418_CR62","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/genes13040694","volume":"13","author":"E D\u2019haenens","year":"2022","unstructured":"D\u2019haenens E et al (2022) Expanding the phenotype of B3GALNT2-related disorders. Genes 13(4):694","journal-title":"Genes"},{"issue":"2","key":"11418_CR63","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/jcmm.13979","volume":"23","author":"Y Dai","year":"2019","unstructured":"Dai Y et al (2019) Whole-exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late-age-of-onset muscular dystrophy-dystroglycanopathy. J Cell Mol Med 23(2):811\u2013818","journal-title":"J Cell Mol Med"},{"issue":"6","key":"11418_CR64","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/hmg\/ddac264","volume":"32","author":"JI de Las Heras","year":"2023","unstructured":"de Las Heras JI et al (2023) Metabolic, fibrotic and splicing pathways are all altered in Emery-Dreifuss muscular dystrophy spectrum patients to differing degrees. Hum Mol Genet 32(6):1010\u20131031","journal-title":"Hum Mol Genet"},{"issue":"7553","key":"11418_CR65","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature14539","volume":"521","author":"Y LeCun","year":"2015","unstructured":"LeCun Y, Bengio Y, Hinton G (2015) Deep learning. Nature 521(7553):436\u2013444","journal-title":"Nature"},{"issue":"9","key":"11418_CR66","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3390\/molecules23092384","volume":"23","author":"D Dana","year":"2018","unstructured":"Dana D et al (2018) Deep learning in drug discovery and medicine: scratching the surface. Molecules 23(9):2384","journal-title":"Molecules"},{"issue":"4","key":"11418_CR67","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.drudis.2020.03.003","volume":"25","author":"S D\u2019Souza","year":"2020","unstructured":"D\u2019Souza S, Prema KV, Balaji S (2020) Machine learning models for drug\u2013target interactions: current knowledge and future directions. Drug Discov Today 25(4):748\u2013756","journal-title":"Drug Discov Today"},{"issue":"5","key":"11418_CR68","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3892\/ijmm.2021.5036","volume":"48","author":"L Chen","year":"2021","unstructured":"Chen L, Tang F, Gao H, Zhang X, Li X, Xiao D (2021) CAPN3: A muscle-specific Calpain with an important role in the pathogenesis of diseases (Review). Int J Mol Med 48(5):203","journal-title":"Int J Mol Med"},{"issue":"8","key":"11418_CR69","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12032-022-01711-1","volume":"39","author":"S Quazi","year":"2022","unstructured":"Quazi S (2022) Artificial intelligence and machine learning in precision and genomic medicine. Med Oncol (Lond) 39(8):120","journal-title":"Med Oncol (Lond)"},{"issue":"1","key":"11418_CR70","doi-asserted-by":"publisher","first-page":"15462","DOI":"10.1038\/s41598-024-65802-x","volume":"14","author":"L Riem","year":"2024","unstructured":"Riem L et al (2024) AI-driven analysis of MRI to measure health and disease progression in FSHD. Sci Rep 14(1):15462","journal-title":"Sci Rep"},{"issue":"24","key":"11418_CR71","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.3390\/cells11244114","volume":"11","author":"V Caputo","year":"2022","unstructured":"Caputo V et al (2022) D4Z4 methylation levels combined with a machine learning pipeline highlight single CpG sites as discriminating biomarkers for FSHD patients. Cells 11(24):4114","journal-title":"Cells"},{"issue":"1","key":"11418_CR72","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-021-23663-2","volume":"12","author":"D Gao","year":"2021","unstructured":"Gao D et al (2021) A deep learning approach to identify gene targets of a therapeutic for human splicing disorders. Nat Commun 12(1):3332","journal-title":"Nat Commun"},{"issue":"1","key":"11418_CR73","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s42003-024-06108-6","volume":"7","author":"S Ito","year":"2024","unstructured":"Ito S et al (2024) A genome-wide association study identifies a locus associated with knee extension strength in older Japanese individuals. Commun Biol 7(1):513","journal-title":"Commun Biol"},{"issue":"Suppl","key":"11418_CR74","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1016\/j.nmd.2023.07.192","volume":"33","author":"A Brureau","year":"2023","unstructured":"Brureau A et al (2023) Evaluation of gene transfer efficiency in a mild model of dystrophic muscle disorder performed by machine learning and linear discriminant analysis. Neuromuscul Disord 33(Suppl):S113\u2013S114","journal-title":"Neuromuscul Disord"},{"key":"11418_CR75","doi-asserted-by":"publisher","first-page":"851491","DOI":"10.3389\/fcvm.2022.851491","volume":"9","author":"CD Vera","year":"2022","unstructured":"Vera CD et al (2022) Treating Duchenne muscular dystrophy: the promise of stem cells, artificial intelligence, and multi-omics. Front Cardiovasc Med 9:851491","journal-title":"Front Cardiovasc Med"},{"key":"11418_CR76","doi-asserted-by":"publisher","first-page":"1395014","DOI":"10.3389\/fphar.2024.1395014","volume":"15","author":"M Saeed","year":"2024","unstructured":"Saeed M et al (2024) Exploring novel natural compound-based therapies for Duchenne muscular dystrophy management: insights from network pharmacology, QSAR modeling, molecular dynamics, and free energy calculations. Front Pharmacol 15:1395014","journal-title":"Front Pharmacol"},{"key":"11418_CR77","unstructured":"Huysmans L, De Wel B, Iterbeke L KC, FM (n.d.) Deep learning approaches for automated classification of muscular dystrophies from MRI. In: [Conference or book details not provided]"},{"issue":"1","key":"11418_CR78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12883-020-02036-0","volume":"21","author":"M Yang","year":"2021","unstructured":"Yang M et al (2021) A deep learning model for diagnosing dystrophinopathies on thigh muscle MRI images. BMC Neurol 21(1):13","journal-title":"BMC Neurol"},{"key":"11418_CR79","doi-asserted-by":"publisher","first-page":"104623","DOI":"10.1016\/j.compbiomed.2021.104623","volume":"135","author":"F Marzola","year":"2021","unstructured":"Marzola F et al (2021) Deep learning segmentation of transverse musculoskeletal ultrasound images for neuromuscular disease assessment. Comput Biol Med 135:104623","journal-title":"Comput Biol Med"},{"issue":"1","key":"11418_CR80","first-page":"17","volume":"1","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Chen C, Ni J, Ni G, Li M, Xu G et al (2020) EMG signal processing for hand motion pattern recognition using machine learning algorithms. Arch Orthop 1(1):17\u201326","journal-title":"Arch Orthop"},{"issue":"4","key":"11418_CR81","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/jpm10040178","volume":"10","author":"AA Speciale","year":"2020","unstructured":"Speciale AA et al (2020) Modelling neuromuscular diseases in the age of precision medicine. J Pers Med 10(4):178","journal-title":"J Pers Med"},{"issue":"8","key":"11418_CR82","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3390\/cells9081773","volume":"9","author":"SS Ahmad","year":"2020","unstructured":"Ahmad SS et al (2020) Implications of insulin-like growth factor-1 in skeletal muscle and various diseases. Cells 9(8):1773","journal-title":"Cells"},{"issue":"8","key":"11418_CR83","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.3390\/ijms23084222","volume":"23","author":"EJ Lee","year":"2022","unstructured":"Lee EJ et al (2022) MIF1 and MIF2 myostatin peptide inhibitors as potent muscle mass regulators. Int J Mol Sci 23(8):4222","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11418-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:44:38Z","timestamp":1768473878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11418-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11418"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11418-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}